Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Breda – page 11

201 clinical trials in Breda, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Breda at a glance
201
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

201 trials in Breda

Open in trial search

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hidradenitis

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Novartis Pharma AG

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Stichting Radboud universitair medisch centrum

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Malignant melanoma

Not recruiting

Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Breda

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and leukemia treatments. Studies evaluate novel drug combinations and targeted therapies to improve patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatment
  • Novel Therapies for AML
  • Melanoma Treatment Optimization

Investigations include combination therapies and treatment discontinuation strategies for various cancer types.

02 Cardiovascular Studies

Research focusing on coronary artery disease and post-procedural care, including innovative diagnostic techniques and antithrombotic strategies.

  • Advanced Imaging Technologies
  • Post-TAVI Treatment Protocols
  • Stroke Prevention Strategies

Emphasis on personalized treatment approaches and diagnostic accuracy improvement.

03 Respiratory Medicine

Clinical trials examining respiratory infections and chronic conditions, including vaccine development and asthma management strategies.

  • RSV Vaccine Studies
  • Asthma Treatment Innovation
  • Lung Cancer Therapies

Focus on both preventive measures and treatment optimizations for respiratory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.